Des Moines Laboratory Update

Date: May 4, 2020

New Orderable: Effective May 4, 2020

Test Name: Coronavirus 2019 Novel (SARS-CoV-2) IgG Ab
Performing Laboratory: MercyOne Des Moines Laboratory
Methodology: Chemiluminescent microparticle immunoassay (CMIA) on the Abbott Architect i2000
Acceptable Specimens: Serum from Gold SST or Red top tube. Green lithium heparin and EDTA plasma are also acceptable.
Minimum Volume: 1 mL
Stability: Refrig: 7 days (preferred) and Frozen: 30 days
CPT: 86769
Client List Price: $58.00
Patient/Insurance Price: $58.00

Notes:
• This assay is for in vitro diagnostic use under FDA Emergency Use Authorization only.
• Testing is only recommended in individuals at least 14 days post-symptom onset or following exposure to individuals with confirmed COVID-19.
• Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
• Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
• Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
• Not to be used to screen units of blood for SARS-CoV-2 infection.
• This test is batched daily, Monday – Friday.
• This test replaces the Mayo Clinic Laboratory COR2G test.

New Diagnosis Codes available in Atlas and AEHR

• Z20.828 Contact with and possible exposure to other viral communicable diseases
• U07.1 2019 nCoV Acute Respiratory Disease

Please contact Andrea Jones, Laboratory Director-Hospital Services, at 515-247-4484 with any questions.

Thank you for choosing MercyOne Des Moines Laboratory.